We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss clinical trial highlights in prostate cancer presented at EMSO 2022. He highlights the results from one of the phase 3 STAMPEDE trials, investigating combination abiraterone and enzalutamide or abiraterone and prednisolone, for metastatic hormone sensitive prostate cancer (mHSPC), […]
In the PROpel trial, abiraterone and olaparib significantly prolonged radiographic progression free survival in patients with metastatic castration-resistant prostate cancer. Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss the biomarker analysis from the primary analysis, and updated overall survival and safety data. The abstract entitled ‘Biomarker […]
Prof. Georgina Long (Melanoma Institute Australia, Wollstonecraft, Australia) joins touchONCOLOGY to discuss clinical trial highlights in melanoma presented at EMSO 2022. She highlights the SWOG S1801 trial, investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma, concluding use of a single-agent pembrolizumab, neoadjuvant therapy improves event-free survival compared to adjuvant therapy in high-risk resectable […]
In patients with resectable melanoma, circulating tumor DNA (ctDNA) detection post-resection may be useful to inform disease state and recurrence risk. Prof. Georgina Long (Melanoma Institute Australia, Wollstonecraft, Australia) joins touchONCOLOGY to discuss CheckMate 915 study and what it taught us about the use of nivolumab plus ipilumab in the adjuvant treatment of melanoma, and […]
Maintenance chemotherapy with oral tegafur-uracil (UFT) after surgery has been shown to prolong survival in lung, breast, gastric and colon cancer. Dr Keiichi Fujiwara (Saitama Medical University International Medical Centre, Saitama, Japan) joins touchONCOLOGY to discuss the phase 3 GOTIC-002 LUFT study results, investigating the efficacy of maintenance chemotherapy using UFT following concurrent chemoradiotherapy for […]
Dr Keiichi Fujiwara joins touchONCOLOGY to discuss his thoughts on the latest clinical trial highlights at European Society for Medical Oncology (ESMO) 2022 in gynaecological cancers, specifically the GOTIC-002 LUFT study. Watch Dr Keiichi Fujiwara’s interview at ESMO 2022, on the Phase 3 GOTIC-002 LUFT study results – chemotherapy with tegafur-uracil for locally advanced cervical […]
Neoadjuvant immunotherapy has shown promising responses in several cancer types. In this touchONCOLOGY interview Dr Myriam Chalabi (Netherlands Cancer Institute, Amsterdam, Netherlands) discusses the NICHE-2 study results, investigating patients with non-metastatic deficient DNA mismatch repair (dMMR) colon cancer, treated with one dose of ipilimumab and two doses of nivolumab and underwent surgery ≤6 weeks of […]
Dr Sara Tolaney joins touchONCOLOGY to discuss the latest clinical trial highlights in breast cancer, at ESMO 2022. She discusses the overall survival data from the TROPiCS-02 study, investigating sacituzumab govitecan-hziy versus treatment of physician’s choice in participants with HR+/HER2- metastatic breast cancer; and the overall survival data from the phase 3 MONARCH 3 trial, […]
Amcenestrant is an optimized oral selective ER degrader (SERD), which is being investigated in the AMEERA-3 (NCT04059484), an open-label phase II randomized study. In this touchONCOLOGY interview, Dr Sara Tolaney (Dana-Farber Cancer Institute, and Brigham and Women’s Hospital, Boston, MA, USA) discusses the phase II study, investigating amcenestrant versus endocrine treatment of physician’s choice in patients […]
Get the latest clinical insights from touchONCOLOGY